Finance and Corporate Governance

Doing business in a responsible way is the basis for long-term viability growth and profitability of a company. 

At Novo Nordisk, we manage our business in a way that delivers competitive financial returns for shareholders through ethical business conduct and transparent business practices while contributing to socio-economic development.

 

Corporate Governance

Corporate Governance refers to the way a company is directed and controlled. Our values are consistent with the principles of good governance. Please click the below links to read more about how we work:

 

 

Share Information

Our B shares are listed on Nasdaq Copenhagen and on the New York Stock Exchange as American Depository Receipts (ADRs). Please refer to the table below.

 

Stock exchange Listing type Stock name
Copenhagen Listed shares DK0060534915 (ISIN)
New York ADRs  NVO

 

 

On the following pages, you can read more about our shares such as share capital and dividend payments. To search and download share price data for a specific date or date range, please use the ‘shareholder tools’.

 

 

Responsible Tax

Our tax approach is to pursue a competitive tax level in a responsible way. This means paying pay tax in jurisdictions where business activity generates profits. 

‘Competitive tax level’ implies achieving a tax level around the peer-group average. ‘Responsible way’ implies doing business in a way that meets expectations of a good corporate citizen. This means paying taxes where profits are earned in accordance with international transfer pricing rules, having a balanced tax risk profile and not engaging in tax-avoidance activities. Therefore, a well-established subsidiary of Novo Nordisk will, in general, pay taxes in the country in which it operates.

More information about our tax approach

 

Long- and short-term investments

We balance growth in the short term with long-term investments. This includes tackling unmet medical needs through research and development (R&D), tailoring production and distribution facilities, and building local healthcare capacity.

An example is our recent collaboration with the University of Oxford on a type 2 diabetes research centre. We will invest GBP 115m over a period of 10 years. For more information, click here.

 

Financial Performance

Novo Nordisk uses long-term financial targets to drive the business towards long-term sustainable growth. These targets help our Executive Management balance growth in the short term with investments in longer-term growth, such as new production facilities and research and development activities. 

For more information about our financial performance, please visit our investor site or the Novo Nordisk Annual Report 2017